Evofem Biosciences, Inc. (EVFM): Cash & Equivalents
$578.0K
As of 2025-12-31
-40.7%
3-year compound annual growth
-58.8%
5-year compound annual growth
-34.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $578.0K | -22.0% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $741.0K | n/a | 2026-03-11, Balance as of period end |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | $2.77M | -64.2% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $7.73M | -84.2% | 2023-04-27, Balance as of period end |
| 2020-12-31 | $48.89M | +214.0% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $15.57M | n/m | 2021-03-04, Balance as of period end |
| 2018-12-31 | $1.33M | +9.8% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $1.21M | -89.4% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $11.48M | -69.6% | 2018-02-26, Balance as of period end |
| 2015-12-31 | $37.75M | -50.3% | 2018-02-26, Balance as of period end |
| 2014-12-31 | $75.95M | n/m | 2017-03-23, Balance as of period end |
| 2013-12-31 | $4.36M | n/a | 2016-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
Compare EVFM, SCYX, CASIF, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗